This is a supplement to EyeWorld Magazine.
Issue link: https://supplements.eyeworld.org/i/1384067
3 | WHITE PAPER | JULY 2021 THERAPEUTIC POTENTIAL OF REGENER-EYES ® OPHTHALMIC SOLUTION IN THE TREATMENT OF DRY EYE DISEASE recruitment of circulating leukocytes in inflamed eyes of DED patients. 5–6,12,14 Alterations in tear production and composition, particularly elevat- ed osmolarity, activates c-Jun N-terminal kinase and NF-kβ signaling pathways in the epithelial cells of DED patients, which result in enhanced secretion of pro-inflammatory cytokine IL-1β. 11 IL-1β induces enhanced expression of adhe- sion molecules on endothelial cells, enabling the massive influx of antigen-presenting den- dritic cells (DCs), macrophages and circulating (sTNFRI, sTNFRII), growth-related oncogene gamma (GRO-γ), fatty acid-binding protein 1 (FABP1) and platelet factor 4 (PF4), which al- leviate eye inflammation, support tear stability, and prevent ocular surface epithelial damage, contributing to the enhanced repair and regener- ation of ocular surface epithelial barrier in DED patients. 1,9,11–13 IL-1Ra is a naturally occurring cytokine that acts as an inhibitor of inflammatory cytokine IL-1β that has a crucially important role in the Molecular mechanisms responsible for beneficial effects of Regener-Eyes®-containing eye drops in the management of DED. Regener-Eyes ® contains a large number of immunoregulatory molecules, trophic and growth factors that attenuate ongoing inflammation and may help to promote repair and regenerate the epithelial barrier at the ocular surface of patients suffering from dry eye disease (DED). By delivering immunoregulatory molecules (interleukin 1 receptor antagonist [IL-1Ra], soluble TNF receptors [sTNFRI, sTNFRII], growth-related oncogene gamma [GRO-γ]), Regener-Eyes® inhibits detrimental immune response in inflamed eyes of DED patients, while, by delivering growth and trophic factors (fatty acid-binding protein [FABP1] and platelet factor 4 [PF4]), Regener-Eyes ® supports tear stability and prevents injury of epithelial cells. This may contribute to the enhanced repair and regeneration of the epithelial barrier at the ocular surface of DED patients. Source: Regener-Eyes ®